Form 4: Seres Therapeutics Director Kurt Graves Acquires Stock Options
SEC Form 4 Filing
Director Kurt Graves acquired stock options in Seres Therapeutics, Inc.
Summary
- On April 4, 2024, Kurt Graves, a director of Seres Therapeutics, Inc. [MCRB], acquired stock options to purchase 60,000 shares of common stock at an exercise price of $0.76.
- The options vest fully on the earlier of April 4, 2025, or the day before the company's 2025 annual meeting of shareholders.
- Following the transaction, Graves directly owns 60,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director, which doesn't inherently indicate positive or negative sentiment but suggests confidence from the director.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This allows investors to monitor the actions of those with privileged information.
Stakeholder Impact
- Shareholders may view the director's stock option acquisition as a sign of confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 04/04/2024 | Date of transaction: Kurt Graves acquired stock options. |
| 04/04/2025 | Options vest in full on the earlier of this date or the day immediately prior to the company's 2025 annual meeting of shareholders. |
| 04/03/2034 | Expiration date of the stock options. |
| 04/08/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.